CAMBRIDGE, April 5, 2016 – Eagle Genomics announces the results of a novel insight on the International Cancer Genome Consortium (https://icgc.org/) data, with over 17,000 patient donors, resulting in a ranking of the most valuable constituent..
Molecular biomarkers are measurable properties that indicate biological state. These are fundamental to the development of today’s precision therapeutics and diagnostics. The current pace of development is phenomenal, but can we go still faster by..
Anthony Finbow has been working since September 2015 in advising Abel Ureta-Vidal (CEO) and the Board of Eagle Genomics in developing the business, in shaping the company’s product vision and in preparing the business for growth. Anthony replaces..
Can I reuse my data ?
As data scientists are fond of telling us, data reuse reduces time to discovery, promotes cost efficiency and ultimately leads to discoveries that would not otherwise have been made. Can organisations currently reuse their..
Evolution provides the unifying framework with which to understand biology. The coherent investigation of genic and genomic data often requires comparative genomics analyses based on whole-genome alignments, sets of homologous genes and other..
BIOCURATION IS THE GLUE
In recent years science has moved rapidly from identifying the first genes involved in cancer (1) to characterising entire cancer genomes (2). These advances herald our understanding the molecular basis of this entire..
Eagle Genomics has secured a position in the IP100 League for 2016. The IP League was created by Metis Partners, and ranks UK companies based on their IP assets and value.
How do life science organisations manage their experimental information and what problems do they face? These are complex questions to answer and it is worth looking at how the information is managed from the individual level (simple case) up to..